RxDoctor Payments Data

Chantel Perry, NP

Adult Health · Houston, TXNPI 1275193344

Payments from drug & device makers

$1,732in general payments, 2019–2025

Across 47 payments — averaging $36.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$304
  • Novartis$202
  • Boehringer Ingelheim$177
  • Boston Scientific$157
  • Edwards Lifesciences$135
  • Medtronic$105
  • plus $652 from 15 others

What the payments were for

  • Food & beverage$1,731100%
  • Education$10%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,732 in reported general payments places this provider in the 70th percentile of 933 adult health providers in Texas.

See all adult health providers in Texas

Medicare billing

Part B allowed, 2024
$1,561
Medicare patients
12
Services billed
25

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan21$28,290
EliquisApixaban13$21,385
JardianceEmpagliflozin16$17,475
Atorvastatin Calcium53$874
Metoprolol Succinate45$760
Carvedilol51$560
Ezetimibe11$424
Losartan Potassium33$346
Amlodipine Besylate41$345
Rosuvastatin Calcium20$335
Potassium Chloride13$223
Isosorbide Mononitrate ErIsosorbide Mononitrate11$223
Spironolactone18$219
Hydralazine Hcl15$214
Lisinopril25$188

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$202$28,29021 claims
Boehringer IngelheimJardiance$177$17,47516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 933 adult health providers in Texas.

Other adult health in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →